Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 10NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Rectal Neoplasms 23Colonic Neoplasms 16Colorectal Neoplasms 14Breast Neoplasms 11Stomach Neoplasms 5Pancreatic Neoplasms 5Bile Duct Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Liver Neoplasms 3Gallbladder Neoplasms 3Breast Neoplasms, Male 3Neoplasm Metastasis 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Waldenstrom Macroglobulinemia 1Turcot syndrome 1Somatostatinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1

Interventions

aldesleukin 23Bevacizumab 17Magnetic Resonance Spectroscopy 15Specimen Handling 12Sunitinib 11Sorafenib 11Interferon-alpha 11cabozantinib 9Cyclophosphamide 9Nivolumab 8Immunoglobulin G 7Disulfides 7temsirolimus 6fludarabine phosphate 5Sirolimus 5Introns 5Fluorouracil 5Erlotinib Hydrochloride 5Chemotherapy, Adjuvant 5sargramostim 4cediranib 4bryostatin 1 4Vorinostat 4Neoadjuvant Therapy 4Ipilimumab 4Interleukin-2 4Interferon alpha-2 4Biopsy 4vandetanib 3ixabepilone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Renal Cell × Capecitabine × Clear all
NCT00121251 2021-04-06

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 13 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡